Mechanisms underlying somatostatin receptor 2 down-regulation of vascular endothelial growth factor expression in response to hypoxia in mouse retinal explants

Journal of Pathology

Volumn 226, Issue 3, 2012, Pages 519-533

  Mei, Sara ^a   Cammalleri, Maurizio ^a   Azara, Danilo ^a   Casini, Giovanni ^b   Bagnoli, Paola ^a   Dal Monte, Massimo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF TUSCIA   (Italy)

Author keywords

HIF 1; immunohistochemistry; immunoprecipitation; octreotide; real time RT PCR; SHP 1; siRNA; STAT3; VEGFR 2; western blotting

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; OCTREOTIDE; PROTEIN TYROSINE PHOSPHATASE SHP 1; SMALL INTERFERING RNA; SOMATOSTATIN RECEPTOR 2; STAT3 PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; EXPLANT; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RETINA;

ANIMALS; CELL HYPOXIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME ACTIVATORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDAZOLES; MICE; MICE, INBRED C57BL; OCTREOTIDE; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, SOMATOSTATIN; RETINA; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84856065334     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3006     Document Type: Article

References (85)

1. Arjamaa O, Nikinmaa M,. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 2006; 83: 473-483. (Pubitemid 43902768)
2. Dal Monte M, Ristori C, Videau C, et al., Expression, localization, and functional coupling of the somatostatin receptor subtype 2 in a mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2010; 51: 1848-1856.
3. Bartoli M, Al-Shabrawey M, Labazi M, et al., HMG-CoA reductase inhibitors (statin) prevents retinal neovascularisation in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2009; 50: 4934-4940.
4. Gariboldi MB, Ravizza R, Monti E,. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 2010; 80: 455-462.
5. Jung JE, Kim HS, Lee CS, et al., Caffeic acid and its synthetic derivative CADPE suppress tumour angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis 2007; 28: 1780-1787. (Pubitemid 47289042)
6. Xu Q, Briggs J, Park S, et al., Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005; 24: 5552-5560. (Pubitemid 43119350)
7. Dasgupta P,. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004; 102: 61-85. (Pubitemid 38429986)
8. Dal Monte M, Cammalleri M, Martini D, et al., Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularisation in the retina: results from transgenic mice. Invest Ophthalmol Vis Sci 2007; 48: 3480-3489. (Pubitemid 351261081)
9. Dal Monte M, Ristori C, Cammalleri M, et al., Effects of somatostatin analogues on retinal angiogenesis in a mouse model of oxygen-induced retinopathy: involvement of the somatostatin receptor subtype 2. Invest Ophthalmol Vis Sci 2009; 50: 3596-3606.
10. Villaume K, Blanc M, Gouysse G, et al., VEGF secretion by neuroendocrine tumour cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 2010; 91: 268-278.
11. Florio T,. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol 2008; 286: 40-48. (Pubitemid 351680234)
12. Kunnumakkara AB, Nair AS, Sung B, et al., Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol Cancer Res 2009; 7: 118-128.
13. Bhattacharya R, Kwon J, Wang E, et al., Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF receptor-2 and attenuates endothelial DNA synthesis, but not migration. J Mol Signal 2008; 3: 8.
14. Cezar-de-Mello PF, Vieira AM, Nascimento-Silva V, et al., ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol 2008; 153: 956-965. (Pubitemid 351328942)
15. Sugano M, Tsuchida K, Maeda T, et al., SiRNA targeting SHP-1 accelerates angiogenesis in a rat model of hindlimb ischemia. Atherosclerosis 2007; 191: 33-39. (Pubitemid 46227426)
16. Lohela M, Bry M, Tammela T, et al., VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21: 154-165.
17. Dal Monte M, Martini D, Ristori C, et al., Hypoxia effects on proangiogenic factors in human umbilical vein endothelial cells: functional role of the peptide somatostatin. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 593-612.
18. Bartoli M, Platt D, Lemtalsi T, et al., VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J 2003; 17: 1562-1564.
19. Ogilvie JM, Speck JD, Lett JM, et al., A reliable method for organ culture of neonatal mouse retina with long-term survival. J Neurosci Methods 1999; 87: 57-65. (Pubitemid 29087086)
20. Eichler W, Yafai Y, Kuhrt H, et al., Hypoxia: modulation of endothelial cell proliferation by soluble factors released by retinal cells. Neuroreport 2001; 12: 4103-4108. (Pubitemid 33152460)
21. Weckbecker G, Lewis I, Albert R, et al., Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Rev Drug Discov 2003; 2: 999-1017. (Pubitemid 37540581)
22. Ristori C, Filippi L, Dal Monte M, et al., Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci 2011; 52: 155-170.
23. Krötz F, Engelbrecht B, Buerkle MA, et al., The tyrosine phosphatase, SHP-1, is a negative regulator of endothelial superoxide formation. J Am Coll Cardiol 2005; 45: 1700-1706. (Pubitemid 40704509)
24. Blaskovich MA, Sun J, Cantor A, et al., Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumour activity against human and murine cancer cells in mice. Cancer Res 2003; 63: 1270-1279. (Pubitemid 36348705)
25. Chun YS, Yeo EJ, Choi E, et al., Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001; 61: 947-954. (Pubitemid 32247383)
26. Tanaka M, Miyajima A,. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003; 149: 39-52.
27. Webb JD, Coleman ML, Pugh CW,. Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci 2009; 66: 3539-3554.
28. Arabaci G, Guo XC, Beebe KD, et al., α-Haloaceto-phenone derivatives as photoreversible covalent inhibitors of protein tyrosine phosphatases. J Am Chem Soc 1999; 121: 5085-5086. (Pubitemid 29269148)
29. Strawn LM, McMahon G, App H, et al., Flk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56: 3540-3545. (Pubitemid 26251650)
30. Casini G, Catalani E, Dal Monte M, et al., Functional aspects of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retinal disease. Histol Histopathol 2005; 20: 615-632. (Pubitemid 40468280)
31. Dal Monte M, Petrucci C, Vasilaki A, et al., Genetic deletion of somatostatin receptor 1 alters somatostatinergic transmission in the mouse retina. Neuropharmacology 2003; 45: 1080-1092. (Pubitemid 37412253)
32. Cristiani R, Petrucci C, Dal Monte M, et al., Somatostatin (SRIF) and SRIF receptors in the mouse retina. Brain Res 2002; 936: 1-14. (Pubitemid 34461928)
33. Kaempf S, Walter P, Salz AK, et al., Novel organotypic culture model of adult mammalian neurosensory retina in co-culture with retinal pigment epithelium. J Neurosci Methods 2008; 173: 47-58.
34. Curatola AM, Moscatelli D, Norris A, et al., Retinal blood vessels develop in response to local VEGF-A signals in the absence of blood flow. Exp Eye Res 2005; 81: 147-158. (Pubitemid 41080096)
35. Bull ND, Johnson TV, Welsapar G, et al., Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies. Invest Ophthalmol Vis Sci 2011; 52: 3309-3320.
36. Yu DY, Cringle SJ,. Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Prog Retin Eye Res 2001; 20: 175-208. (Pubitemid 32153715)
37. Chen Z, Han Z,. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 2008; 28: 185-200. (Pubitemid 351281185)
38. Fong GH,. Regulation of angiogenesis by oxygen sensing mechanisms. J Mol Med 2009; 87: 549-560.
39. Lamoke F, Labazi M, Montemari A, et al., Trans-chalcone prevents VEGF expression and retinal neovascularisation in the ischemic retina. Exp Eye Res 2011; 93: 350-354.
40. Gray MJ, Zhang J, Ellis LM, et al., HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005; 24: 3110-3120. (Pubitemid 40695080)
41. Ren H, Liu NY, Song XF, et al., A novel specific application of pyruvate protects the mouse retina against white light damage: differential stabilization of HIF-1α and HIF-2α. Invest Ophthalmol Vis Sci 2011; 52: 3112-3118.
42. Byfield G, Budd S, Hartnett ME,. The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularisation in a ROP rat model. Invest Ophthalmol Vis Sci 2009; 50: 3360-3365.
43. Crosson LA, Kroes RA, Moskal JR, et al., Gene expression patterns in hypoxic and post-hypoxic adult rat retina with special reference to the NMDA receptor and its interactome. Mol Vis 2009; 15: 296-311.
44. Mechoulam H, Pierce EA,. Expression and activation of STAT3 in ischemia-induced retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 4409-4416. (Pubitemid 44268952)
45. Kaur C, Sivakumar V, Foulds WS, et al., Cellular and vascular changes in the retina of neonatal rats after an acute exposure to hypoxia. Invest Ophthalmol Vis Sci 2009; 50: 5364-5374.
46. Kaur C, Sivakumar V, Foulds WS,. Early response of neurons and glial cells to hypoxia in the retina. Invest Ophthalmol Vis Sci 2006; 47: 1126-1141.
47. Wan J, Ma J, Mei J, et al., The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells. J Exp Clin Cancer Res 2009; 28: 150.
48. Jeong CH, Lee HJ, Cha JH, et al., Hypoxia-inducible factor-1 alpha inhibits self-renewal of mouse embryonic stem cells in vitro via negative regulation of the leukemia inhibitory factor-STAT3 pathway. J Biol Chem 2007; 282: 13672-13679.
49. Vollmer S, Kappler V, Kaczor J, et al., Hypoxia-inducible factor 1alpha is up-regulated by oncostatin M and participates in oncostatin M signaling. Hepatology 2009; 50: 253-260.
50. Xu B, Doughman Y, Turakhia M, et al., Partial rescue of defects in Cited2-deficient embryos by HIF-1alpha heterozygosity. Dev Biol 2007; 301: 130-140. (Pubitemid 46001381)
51. Boehm BO, Lang GK, Jehle PM, et al., Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001; 33: 300-306. (Pubitemid 32579247)
52. Grant MB, Mames RN, Fitzgerald C, et al., The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000; 23: 504-509. (Pubitemid 30185795)
53. Palii SS, Afzal A, Shaw LC, et al., Nonpeptide somatostatin receptor agonists specifically target ocular neovascularisation via the somatostatin type 2 receptor. Invest Ophthalmol Vis Sci 2008; 49: 5094-5102.
54. Wilkinson-Berka JL, Lofthouse S, Jaworski K, et al., An antisense oligonucleotide targeting the growth hormone receptor inhibits neovascularisation in a mouse model of retinopathy. Mol Vis 2007; 13: 1529-1538. (Pubitemid 47354373)
55. Higgins MD, Yan Y, Schrier BK,. Somatostatin analogs inhibit neonatal retinal neovascularisation. Exp Eye Res 2002; 74: 553-559. (Pubitemid 34757010)
56. Noman MZ, Buart S, Van Pelt J, et al., The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumour susceptibility to CTL-mediated cell lysis. J Immunol 2009; 182: 3510-3521.
57. Pirotte S, Lamour V, Lambert V, et al., Dentin matrix protein 1 induces membrane expression of VE-cadherin on endothelial cells and inhibits VEGF-induced angiogenesis by blocking VEGFR-2 phosphorylation. Blood 2011; 117: 2515-2526.
58. Kim JH, Kim MH, Jo DH, et al., The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation. Biomaterials 2011; 32: 1865-1871.
59. Kim JH, Kim JH, Lee YM, et al., Decursin inhibits retinal neovascularization via suppression of VEGFR-2 activation. Mol Vis 2009; 15: 1868-1875.
60. Ojima T, Takagi H, Suzuma K, et al., EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am J Pathol 2006; 168: 331-339. (Pubitemid 43062584)
61. DeNiro M, Alsmadi O, Al-Mohanna F,. Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis. Exp Eye Res 2009; 89: 700-717.
62. 5) differentially influences human retinal pigment epithelium cell viability. Acta Ophthalmol 2010; 88: e228-e233.
63. Theodoropoulou M, Zhang J, Laupheimer S, et al., Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumour cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006; 66: 1576-1582. (Pubitemid 43259940)
64. Mastrodimou N, Kiagiadaki F, Hodjarova M, et al., Somatostatin receptors (sst2) regulate cGMP production in rat retina. Regul Pept 2006; 133: 41-46. (Pubitemid 41820334)
65. Adams RL, Adams IP, Lindow SW, et al., Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 2005; 92: 1493-1498. (Pubitemid 40705017)
66. Watson JC, Balster DA, Gebhardt BM, et al., Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 2001; 85: 266-272. (Pubitemid 32695750)
67. Ergorul C, Ray A, Huang W, et al., Levels of vascular endothelial growth factor-A165b (VEGF-A165b) are elevated in experimental glaucoma. Mol Vis 2008; 14: 1517-1524.
68. May CA, Ohlmann AV, Hammes H, et al., Proteins with an endostatin-like domain in a mouse model of oxygen-induced retinopathy. Exp Eye Res 2006; 82: 341-348. (Pubitemid 43122121)
69. Famiglietti EV, Stopa EG, McGookin ED, et al., Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res 2003; 969: 195-204. (Pubitemid 36369627)
70. Feeney SA, Simpson DA, Gardiner TA, et al., Role of vascular endothelial growth factor and placental growth factors during retinal vascular development and hyaloid regression. Invest Ophthalmol Vis Sci 2003; 44: 839-847. (Pubitemid 36159736)
71. Gerhardinger C, Brown LF, Roy S, et al., Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol 1998; 152: 1453-1462. (Pubitemid 28275004)
72. Gilbert RE, Vranes D, Berka JL, et al., Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998; 78: 1017-1027. (Pubitemid 28378215)
73. Lutty GA, McLeod DS, Merges C, et al., Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996; 114: 971-977. (Pubitemid 26271463)
74. Lieblein JC, Ball S, Hutzen B, et al., STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer 2008; 8: 302.
75. Chattopadhyay S, Tracy E, Liang P, et al., Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem 2007; 282: 3014-3026. (Pubitemid 47084348)
76. Kroening S, Neubauer E, Wessel J, et al., Hypoxia interferes with connective tissue growth factor (CTGF) gene expression in human proximal tubular cell lines. Nephrol Dial Transplant 2009; 24: 3319-3325.
77. Palen DI, Belmadani S, Lucchesi PA, et al., Role of SHP-1, Kv.1.2, and cGMP in nitric oxide-induced ERK1/2 MAP kinase dephosphorylation in rat vascular smooth muscle cells. Cardiovasc Res 2005; 68: 268-277. (Pubitemid 41428423)
78. Rozen S, Skaletsky H,. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-386.
79. Wang X, Seed B,. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003; 31: e154.
80. Pattyn F, Speleman F, De Paepe A, et al., RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res 2003; 31: 122-123. (Pubitemid 36150349)
81. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
82. Sättler MB, Merkler D, Maier K, et al., Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004; 11: S181-S192.
83. Zhu X, Li A, Brown B, et al., Mouse cone arrestin expression pattern: light induced translocation in cone photoreceptors. Mol Vis 2002; 8: 462-471. (Pubitemid 36153639)
84. Haeseleer F, Sokal I, Verlinde CL, et al., Five members of a novel Ca(2 +)-binding protein (CABP) subfamily with similarity to calmodulin. J Biol Chem 2000; 275: 1247-1260. (Pubitemid 30051178)
85. Banerjee A, Roach MC, Wall KA, et al., A monoclonal antibody against the type II isotype of beta-tubulin. Preparation of isotypically altered tubulin. J Biol Chem 1988; 263: 3029-3034. (Pubitemid 18062960)